What Factors Propelled The Growth Of The Bioengineered Protein Drugs Market In The Past?
The bioengineered protein drugs market has seen considerable growth due to a variety of factors.
•In recent years, the market size for bioengineered protein drugs has experienced significant growth. It is set to increase from $406.39 billion in 2024 to $439.29 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 8.1%.
Factors contributing to this growth during the historical era include improved comprehension of diseases, regulatory authorizations, a surge in chronic disease prevalence, collaborations and partnerships, and market expansion.
What Is The Projected Growth And Market Size For The Bioengineered Protein Drugs Sector?
The bioengineered protein drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for bioengineered protein drugs is anticipated to experience robust expansion in the upcoming years, swelling to $604.42 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 8.3%.
The predicted growth within this period can be linked to emerging trends such as personalized medicine, a broader range of therapeutic uses, the rise of new markets, concentration on rare illnesses, and advancements in healthcare infrastructure. Key trends expected during this forecast period encompass progress in protein engineering, a mounting emphasis on monoclonal antibodies, individualized medicine as well as targeted therapies, the advent of advanced biologics, and refinement in the manufacturing process.
What Are The Core Factors Supporting Growth In The Bioengineered Protein Drugs Market?
The surge in chronic disease incidence is projected to be a key factor in driving bioengineered protein drug market expansion. Chronic diseases are long-term conditions that necessitate continuous medical care and limit physical activities. Bioengineered protein drugs, which include tailored protein therapies, offer a valuable tool in the fight against chronic diseases, particularly in oncology and regenerative medicine, and are designed using combinatorial and logical approaches. For example, the World Health Organization's 2022 Highlights released in September 2022 reports that 41 million of the 74% of global annual deaths due to noncommunicable or chronic illnesses occurred due to conditions like cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes, totaling 17.9 million, 9.3 million, 4.1 million, and 2.0 million deaths, respectively. In this context, the escalation of chronic diseases is fuelling the demand for bioengineered protein drugs.
What Are The Major Segments Within The Global Bioengineered Protein Drugs Market?
The bioengineered protein drugs market covered in this report is segmented –
1) By Drug Type: Recombinant Protein, Vaccine, Peptide Antibiotics, Therapeutic Enzymes, Other Drug Type
2) By Technology: Bioreactors, Fractionation, Genetically Modified Organisms, Genetic Engineering, Pharming, Cell Culture, Microbial Cell Fermentation, Other Technology
3) By Application: Autoimmune, Heart, Congenital, Infectious Diseases, Cancer, Diabetes, Arthritis, Other Application
4) By End User: Pharmaceutical, Contract Research Organizations, Research Institutes, Biotechnology Companies
Subsegments:
1) By Recombinant Protein: Monoclonal Antibodies, Hormones, Cytokines
2) By Vaccine: Recombinant Vaccines, DNA Vaccines
3) By Peptide Antibiotics: Lipopeptide Antibiotics, Glycopeptide Antibiotics
4) By Therapeutic Enzymes: Enzyme Replacement Therapies, Biosimilar Enzymes
5) By Other Drug Type: Fusion Proteins, Antibody-Drug Conjugates (ADCs)
Pre-Book The Bioengineered Protein Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Bioengineered Protein Drugs Market?
Major firms in the bioengineered protein drug market are leveraging strategic partnerships to supply crucial bioengineered protein medicines to businesses and government entities. This typically entails companies capitalizing on each other's abilities and resources for mutual advantages and accomplishments. For instance, Future Fields, a biotech firm based in Canada, joined forces with Jenthera Therapeutics, another biotechnology company from Canada concentrating on the creation of pioneering therapies for intricate and rare diseases, in June 2023. Their objective, through this collaboration, is to produce an innovative protein to combat cancer employing the EntoEngine platform from Future Fields, which allows for economically viable and environmentally friendly large-scale production.
Who Are the Key Players in the Bioengineered Protein Drugs Market?
Major companies operating in the bioengineered protein drugs market include:
• Abbvie Inc.
• Amgen Inc.
• Astrazeneca PLC
• Bayer HealthCare Pharmaceuticals LLC
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Johnson & Johnson
• Novartis AG
• Novo Nordisk A/S
• Sanofi S.A.
• Grifols S.A.
• Adma Biologics Inc.
• CSL Limited
• Abbott Laboratories
• Baxter International Inc.
• Fresenius Kabi AG
• Merck & Co. Inc.
• Pfizer Inc.
• Biogen Inc.
• Bristol-Myers Squibb Company
• Genentech Inc.
• Lonza Group AG
• MedImmune LLC
• Regeneron Pharmaceuticals Inc.
• Shire plc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Shanghai United Cell Biotechnology Co. Ltd.
• Panacea Biotec Ltd.
What Is The Most Dominant Region In The Bioengineered Protein Drugs Market?
North America was the largest region in the bioengineered protein drugs market in 2024. The regions covered in the bioengineered protein drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
